Publications by authors named "Robert Hamatake"

Claim this Profile
T
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.
Haiyan Ma, Tien Huey Lim, Apinya Leerapun, Martin Weltman, Jidong Jia, Robert Hamatake

JHEP Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants.
Yanli Deng, Fiona Campbell, Kelong Han, Dickens Theodore, Mark Deeg, Robert Hamatake

J Viral Hepat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
Wieslaw M Kazmierski, Sam Baskaran, Jill T Walker, Nagaraju Miriyala, Ramu Meesala, Robert Hamatake

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Kelong Han, Jennifer Cremer, Robert Elston, Stuart Oliver, Sharon Baptiste-Brown, Robert Hamatake

Clin Pharmacol Drug Dev· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
Gaetan Billioud, Robert L Kruse, Melissa Carrillo, Christina Whitten-Bauer, Dacao Gao, Robert Hamatake

J Hepatol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.
Daniel Rycroft, Jane Sosabowski, Edward Coulstock, Marie Davies, John Morrey, Robert Hamatake

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Jeffrey J Pouliot, Michael Thomson, Mi Xie, Joseph Horton, John Johnson, Robert Hamatake

Antimicrob Agents Chemother· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.
Mette J Nielsen, Sanne S Veidal, Morten A Karsdal, Diana J Ørsnes-Leeming, Ben Vainer, Robert Hamatake

Liver Int· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.
Jill Walker, Renae Crosby, Amy Wang, Ermias Woldu, Jessica Vamathevan, Robert Hamatake

Antimicrob Agents Chemother· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Stephen Gardner, Amy Cutrell, Cindy Elko-Simms, Kimberly Adkison, Robert Hamatake

Liver Int· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C replication inhibitors that target the viral NS4B protein.
John F Miller, Pek Y Chong, J Brad Shotwell, John G Catalano, Vincent W-F Tai, Robert K Hamatake

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
Andrew Maynard, Renae M Crosby, Byron Ellis, Robert Hamatake, Zhi Hong

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.
Wieslaw M Kazmierski, Andrew Maynard, Maosheng Duan, Sam Baskaran, Janos Botyanszki, Robert Hamatake

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations.
Dipankar Bhattacharya, Israrul H Ansari, Robert Hamatake, Jill Walker, Wieslaw M Kazmierski

J Gen Virol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Christian Voitenleitner, Renae Crosby, Jill Walker, Katja Remlinger, Jessica Vamathevan, Robert Hamatake

Antimicrob Agents Chemother· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Xianfeng Li, Yang Liu, Yong-Kang Zhang, Jacob J Plattner, Stephen J Baker, Robert Hamatake

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
Maosheng Duan, Wieslaw Kazmierski, Renae Crosby, Margaret Gartland, Jinjing Ji, Robert Hamatake

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
Wieslaw M Kazmierski, Robert Hamatake, Maosheng Duan, Lois L Wright, Gary K Smith

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C genotype 1a replicon improved through introduction of fitness mutations.
Christian Voitenleitner, Jill Bechtel, Ann Arfsten, Robert Hamatake

Biotechniques· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus.
Samantha Blackham, Andrew Baillie, Fadel Al-Hababi, Katja Remlinger, Shihyun You, Robert Hamatake

J Virol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Cory Iverson, Gary Larson, Chon Lai, Li-Tain Yeh, Claudia Dadson, Robert Hamatake

Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.
Charles E Mazzucco, Robert K Hamatake, Richard J Colonno, Daniel J Tenney

Antimicrob Agents Chemother· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors.
Esmir Gunic, Suetying Chow, Frank Rong, Kanda Ramasamy, Anneke Raney, Robert K Hamatake

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication.
Esmir Gunic, Jean-Luc Girardet, Kanda Ramasamy, Vesna Stoisavljevic-Petkov, Suetying Chow, Robert K Hamatake

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study.
Shunqi Yan, Todd Appleby, Gary Larson, Jim Z Wu, Robert K Hamatake

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis